Hong Kong
· Delayed Price · Currency is HKD InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 19.38 billion. The enterprise value is 14.46 billion.
| Market Cap | 19.38B |
| Enterprise Value | 14.46B |
Important Dates
The last earnings date was Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has decreased by -0.90% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.76B |
| Shares Change (YoY) | -0.90% |
| Shares Change (QoQ) | -15.41% |
| Owned by Insiders (%) | 21.37% |
| Owned by Institutions (%) | 35.92% |
| Float | 1.30B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.87 |
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -30.83 |
| EV / Sales | 13.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.37, with a Debt / Equity ratio of 0.23.
| Current Ratio | 7.37 |
| Quick Ratio | 6.22 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.43 |
Financial Efficiency
Return on equity (ROE) is -6.50% and return on invested capital (ROIC) is -3.80%.
| Return on Equity (ROE) | -6.50% |
| Return on Assets (ROA) | -3.37% |
| Return on Invested Capital (ROIC) | -3.80% |
| Return on Capital Employed (ROCE) | -6.25% |
| Revenue Per Employee | 986,434 |
| Profits Per Employee | -430,587 |
| Employee Count | 1,089 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.25% in the last 52 weeks. The beta is 1.03, so InnoCare Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +95.25% |
| 50-Day Moving Average | 7.79 |
| 200-Day Moving Average | 6.18 |
| Relative Strength Index (RSI) | 61.78 |
| Average Volume (20 Days) | 9,709,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 1.07 billion and -468.91 million in losses. Loss per share was -0.28.
| Revenue | 1.07B |
| Gross Profit | 926.90M |
| Operating Income | -554.94M |
| Pretax Income | -481.64M |
| Net Income | -468.91M |
| EBITDA | -493.23M |
| EBIT | -554.94M |
| Loss Per Share | -0.28 |
Balance Sheet
The company has 6.62 billion in cash and 1.68 billion in debt, giving a net cash position of 4.95 billion or 2.81 per share.
| Cash & Cash Equivalents | 6.62B |
| Total Debt | 1.68B |
| Net Cash | 4.95B |
| Net Cash Per Share | 2.81 |
| Equity (Book Value) | 7.18B |
| Book Value Per Share | 4.47 |
| Working Capital | 7.19B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 86.29%, with operating and profit margins of -51.66% and -43.65%.
| Gross Margin | 86.29% |
| Operating Margin | -51.66% |
| Pretax Margin | -44.84% |
| Profit Margin | -43.65% |
| EBITDA Margin | -45.91% |
| EBIT Margin | -51.66% |
| FCF Margin | n/a |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.90% |
| Shareholder Yield | 0.90% |
| Earnings Yield | -2.42% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |